东宝生物(300239)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300239 东宝生物

已收盘 07-30 15:00:00

{"stockData":{"symbol":"300239","market":"SZ","secType":"STK","nameCN":"东宝生物","latestPrice":5.95,"timestamp":1753858986000,"preClose":5.96,"halted":0,"volume":10875301,"delay":0,"changeRate":-0.0017,"floatShares":590000000,"shares":594000000,"eps":0.1332,"marketStatus":"已收盘","change":-0.01,"latestTime":"07-30 15:00:00","open":5.96,"high":6.01,"low":5.88,"amount":64781100,"amplitude":0.0218,"askPrice":5.96,"askSize":395,"bidPrice":5.95,"bidSize":428,"shortable":0,"etf":0,"ttmEps":0.1332,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.96,"symbolType":"stock","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":6.56,"lowLimit":5.36,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":593607933,"isCdr":false,"pbRate":2.09,"roa":"--","peRate":44.66967,"roe":"1.1%","epsLYR":0.1448,"committee":-0.788976,"marketValue":3532000000,"turnoverRate":0.0184,"status":1,"floatMarketCap":3509000000},"requestUrl":"/m/hq/s/300239","defaultTab":"news","newsList":[{"id":"2543668318","title":"每周股票复盘：东宝生物（300239）2024年度分红派息及转股价格调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2543668318","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543668318?lang=zh_cn&edition=full","pubTime":"2025-06-14 14:05","pubTimestamp":1749881111,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘，东宝生物报收于5.6元，较上周的5.58元上涨0.36%。公司公告汇总包头东宝生物技术股份有限公司发布2024年度分红派息实施公告。本次权益分派的股权登记日为2025年6月16日，除权除息日为2025年6月17日。2024年5月31日，公司完成2023年度分红派息，转股价格由6.67元/股调整为6.65元/股。包头东宝生物技术股份有限公司董事会2025年6月10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400013109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300239","BK0077"],"gpt_icon":0},{"id":"2541892463","title":"每周股票复盘：东宝生物（300239）实施权益分派期间“东宝转债”暂停转股","url":"https://stock-news.laohu8.com/highlight/detail?id=2541892463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541892463?lang=zh_cn&edition=full","pubTime":"2025-06-07 10:01","pubTimestamp":1749261675,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，东宝生物报收于5.58元，较上周的5.52元上涨1.09%。本周关注点公司公告汇总：东宝生物将于2025年6月9日起暂停“东宝转债”转股直至2024年度权益分派完成公司公告汇总东宝生物发布公告称，因即将实施2024年度权益分派，根据相关规定，自2025年6月9日起至2024年度权益分派股权登记日止，“东宝转债”将暂停转股。暂停期间，“东宝转债”仍可正常交易。恢复转股时间为2024年度权益分派股权登记日后的第一个交易日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700009862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300239","BK0077"],"gpt_icon":0},{"id":"2537094321","title":"东宝生物：获得国产保健食品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2537094321","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537094321?lang=zh_cn&edition=full","pubTime":"2025-05-22 19:31","pubTimestamp":1747913495,"startTime":"0","endTime":"0","summary":"格隆汇5月22日丨东宝生物(300239.SZ)公布，公司“倍优免牌骨胶原蛋白维生素C粉”产品于近日完成国产保健食品注册工作，并获得国家市场监督管理总局发放的国产保健食品注册证书。“倍优免牌骨胶原蛋白维生素C粉”保健食品注册证书的取得，有利于进一步丰富公司的产品线，提升公司在保健食品领域的竞争力，符合公司大健康产业布局的战略规划，对公司发展具有积极意义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052219314494ff21a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052219314494ff21a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0028","BK0239","BK0188","000807","300239","BK0233"],"gpt_icon":0},{"id":"2537431439","title":"东宝生物最新公告：公司产品倍优免牌骨胶原蛋白维生素C粉获得国产保健食品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2537431439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537431439?lang=zh_cn&edition=full","pubTime":"2025-05-22 19:30","pubTimestamp":1747913444,"startTime":"0","endTime":"0","summary":"东宝生物(300239.SZ)公告称，公司产品“倍优免牌骨胶原蛋白维生素C粉”于近日完成国产保健食品注册工作，并获得国家市场监督管理总局发放的国产保健食品注册证书。该产品具有有助于增强免疫力的保健功能，有效期至2030年04月29日。此注册证书的取得有利于丰富公司产品线，提升公司在保健食品领域的竞争力，符合公司大健康产业布局的战略规划，对公司发展具有积极意义。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200031738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300239","BK0239","BK0028"],"gpt_icon":0},{"id":"2535046871","title":"东宝生物获得实用新型专利授权：“酶粉溶解设备和明胶原料处理系统”","url":"https://stock-news.laohu8.com/highlight/detail?id=2535046871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535046871?lang=zh_cn&edition=full","pubTime":"2025-05-16 02:17","pubTimestamp":1747333068,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示东宝生物新获得一项实用新型专利授权，专利名为“酶粉溶解设备和明胶原料处理系统”，专利申请号为CN202421732659.1，授权日为2025年5月16日。该酶粉溶解设备能够对酶粉和纯净水进行充分搅拌，降低了配置酶剂溶液的劳动强度；而且酶剂溶液在相对封闭的搅拌腔中形成，避免人体与酶剂溶液直接接触，从而防止酶剂溶液危害工人身体健康。今年以来东宝生物新获得专利授权2个，较去年同期增加了100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051600001041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0028","300239"],"gpt_icon":0},{"id":"2529554306","title":"图解东宝生物一季报：第一季度单季净利润同比减26.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529554306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529554306?lang=zh_cn&edition=full","pubTime":"2025-04-24 01:27","pubTimestamp":1745429275,"startTime":"0","endTime":"0","summary":"证券之星消息，东宝生物2025年一季报显示，公司主营收入1.88亿元，同比下降22.23%；归母净利润1904.48万元，同比下降26.64%；扣非净利润1776.17万元，同比下降24.81%；负债率33.71%，投资收益-57.61万元，财务费用-22.32万元，毛利率25.06%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400001332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300239"],"gpt_icon":0},{"id":"2529482635","title":"东宝生物(300239.SZ)发布2024年度业绩，归母净利润8598.27万元，同比下降28.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529482635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529482635?lang=zh_cn&edition=full","pubTime":"2025-04-23 22:49","pubTimestamp":1745419763,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东宝生物(300239.SZ)发布2024年年度报告，公司2024年度营业收入8.85亿元，同比下降9.19%;归属于上市公司股东的净利润8598.27万元，同比下降28.28%;归属于上市公司股东的扣除非经常性损益的净利润7908.93万元，同比下降28.17%;基本每股收益0.1448元/股。拟每10股派发现金红利0.25元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300239"],"gpt_icon":0},{"id":"2529943639","title":"东宝生物(300239.SZ)发布一季度业绩，归母净利润1904.48万元，同比下降26.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529943639","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529943639?lang=zh_cn&edition=full","pubTime":"2025-04-23 22:46","pubTimestamp":1745419560,"startTime":"0","endTime":"0","summary":"东宝生物(300239.SZ)发布2025年第一季度报告，公司2025年第一季度营业收入1.88亿元，同比下降22.23%;归属于上市公司股东的净利润1904.48万元，同比下降26.64%;归属于上市公司股东的扣除非经常性损益的净利润1776.17万元，同比下降24.81%;基本每股收益0.0323元/股。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-23/doc-ineuekxr4246799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300239"],"gpt_icon":0},{"id":"2529864926","title":"东宝生物(300239.SZ)：一季度净利润1904万元 同比下降26.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529864926","media":"格隆汇","labels":["dataReport","viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529864926?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:19","pubTimestamp":1745414355,"startTime":"0","endTime":"0","summary":"格隆汇4月23日丨东宝生物(300239.SZ)公布第一季度报告，营业收入1.88亿元，同比下降22.23%，归属于上市公司股东的净利润1904万元，同比下降26.64%，归属于上市公司股东的扣除非经常性损益的净利润1776万元，同比下降24.81%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/23211949805467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"东宝生物(300239.SZ)：一季度净利润1904万元 同比下降26.64%","news_tag":"dataReport,viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300239"],"gpt_icon":0},{"id":"2529507928","title":"东宝生物最新公告：2025年第一季度营业收入同比下降22.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529507928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529507928?lang=zh_cn&edition=full","pubTime":"2025-04-23 20:19","pubTimestamp":1745410763,"startTime":"0","endTime":"0","summary":"东宝生物(300239.SZ)公告称，2025年第一季度实现营业收入1.88亿元，同比下降22.23%；归属于上市公司股东的净利润为1904.48万元，同比下降26.64%。主要原因是本期收到的税费返还、其他与经营活动有关的现金低于上期，以及本期购买商品、接受劳务支付的现金高于上期综合所致。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300037312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300239"],"gpt_icon":0},{"id":"2512902388","title":"因募资管理违规收“双函” 东宝生物内部治理短板亟待补全","url":"https://stock-news.laohu8.com/highlight/detail?id=2512902388","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512902388?lang=zh_cn&edition=full","pubTime":"2025-02-18 10:06","pubTimestamp":1739844360,"startTime":"0","endTime":"0","summary":"　　近日，东宝生物因募集资金管理违规，接连收到内蒙古证监局和深圳证券交易所的警示函与监管函。这一事件凸显了公司在资金管理、信息披露和募投项目执行方面存在的多重问题，不仅反映了东宝生物的内部管理漏洞，也再次警示了资本市场对于上市公司合规性的高要求。　　在一系列违规行为的背后，东宝生物的财务状况也难言乐观。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-02-18/doc-inekwkcm6013910.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-02-18/doc-inekwkcm6013910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300239","BK0077","BK0239","BK0028"],"gpt_icon":0},{"id":"2512909747","title":"信息披露违规！东宝生物被出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2512909747","media":"新浪证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512909747?lang=zh_cn&edition=full","pubTime":"2025-02-18 10:01","pubTimestamp":1739844060,"startTime":"0","endTime":"0","summary":"　　2月17日，内蒙古证监局发布公告，包头东宝生物技术股份有限公司在募集资金管理及使用方面存在多项问题，被采取出具警示函的行政监管措施，并记入证券期货市场诚信档案。　　公开资料显示，东宝生物主要从事明胶和胶原蛋白及其衍生产品的研发、设计、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-18/doc-inekwkci7264287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0077","300239"],"gpt_icon":0},{"id":"2512946590","title":"东宝生物因未及时披露公司重大事件等违规行为被内蒙古证监局出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2512946590","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512946590?lang=zh_cn&edition=full","pubTime":"2025-02-17 19:01","pubTimestamp":1739790069,"startTime":"0","endTime":"0","summary":"证券之星消息，2月17日东宝生物公开信息显示，包头东宝生物技术股份有限公司因未及时披露公司重大事件,未依法履行其他职责被内蒙古证监局出具警示函。上述行为违反了《上市公司信息披露管理办法》第三条第一款、《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》第十二条第一款有关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021700026698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","300239"],"gpt_icon":0},{"id":"2512294660","title":"东宝生物因未及时披露公司重大事件等违规行为被深圳证券交易所采取监管措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2512294660","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512294660?lang=zh_cn&edition=full","pubTime":"2025-02-17 19:01","pubTimestamp":1739790069,"startTime":"0","endTime":"0","summary":"证券之星消息，2月17日东宝生物公开信息显示，包头东宝生物技术股份有限公司因未及时披露公司重大事件,未依法履行其他职责被深圳证券交易所创业板公司管理部采取监管措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021700026696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","399001","BK0239","BK0028","300239"],"gpt_icon":0},{"id":"2512906914","title":"东宝生物(300239.SZ)收到内蒙古证监局警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2512906914","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512906914?lang=zh_cn&edition=full","pubTime":"2025-02-17 16:44","pubTimestamp":1739781848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东宝生物 公告，公司收到内蒙古证监局现场检查出具的《关于对包头东宝生物技术股份有限公司采取出具警示函措施的决定》。二是公司公告募投项目“废水资源综合利用项目”实施期限至2023年4月30日，检查发现项目2023年4月30日至2024年9月仍有募集资金投入使用，2024年9月完成全线设备带料调试具备正式生产条件，实际投资进度与披露的投资计划存在差异，但公司未及时披露具体原因及调整募集资金投资计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300239","BK0028","BK0239","BK0077"],"gpt_icon":0},{"id":"2510493653","title":"东宝生物（300239）2月12日主力资金净卖出450.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510493653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510493653?lang=zh_cn&edition=full","pubTime":"2025-02-12 15:29","pubTimestamp":1739345389,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月12日收盘，东宝生物报收于5.74元，下跌1.2%，换手率1.82%，成交量10.71万手，成交额6141.15万元。2月12日的资金流向数据方面，主力资金净流出450.26万元，占总成交额7.33%，游资资金净流入49.53万元，占总成交额0.81%，散户资金净流入400.73万元，占总成交额6.53%。东宝生物主营业务：明胶和胶原蛋白及其衍生产品的研发、设计、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021200019699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300239","BK0028","BK0239","BK0077"],"gpt_icon":0},{"id":"2510600875","title":"东宝生物（300239）2月11日主力资金净买入1039.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510600875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510600875?lang=zh_cn&edition=full","pubTime":"2025-02-11 15:22","pubTimestamp":1739258529,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月11日收盘，东宝生物报收于5.81元，上涨2.29%，换手率3.5%，成交量20.64万手，成交额1.19亿元。2月11日的资金流向数据方面，主力资金净流入1039.31万元，占总成交额8.72%，游资资金净流出263.46万元，占总成交额2.21%，散户资金净流出775.85万元，占总成交额6.51%。东宝生物主营业务：明胶和胶原蛋白及其衍生产品的研发、设计、生产、销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021100018649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300239","BK0077","BK0239","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753876854208,"stockEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0347},{"period":"3month","weight":0.1737},{"period":"6month","weight":0.1273},{"period":"1year","weight":0.3333},{"period":"ytd","weight":-0.0438}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"包头东宝生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22262人(较上一季度减少8.75%)","perCapita":"26491股","listingDate":"2011-07-06","address":"内蒙古自治区包头市九原区稀土高新技术产业开发区黄河大街46号","registeredCapital":"59360万元","survey":"　　包头东宝生物技术股份有限公司的主营业务是从事明胶和胶原蛋白及其衍生产品的研发、设计、生产、销售。公司的主要产品是明胶、代血浆明胶、空心胶囊、胶原蛋白。","listedPrice":9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东宝生物(300239)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东宝生物(300239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东宝生物,300239,东宝生物股票,东宝生物股票老虎,东宝生物股票老虎国际,东宝生物行情,东宝生物股票行情,东宝生物股价,东宝生物股市,东宝生物股票价格,东宝生物股票交易,东宝生物股票购买,东宝生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东宝生物(300239)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东宝生物(300239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}